News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,330 Results
Type
Article (5097)
Company Profile (24)
Press Release (227209)
Multimedia
Podcasts (3)
Webinars (4)
Section
Business (82262)
Career Advice (463)
Deals (15056)
Drug Delivery (8)
Drug Development (19079)
Employer Resources (30)
FDA (3684)
Job Trends (3909)
News (120198)
Policy (7519)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (296)
Accelerated approval (7)
Adcomms (4)
Allergies (14)
Alliances (14810)
ALS (38)
Alzheimer's disease (295)
Antibody-drug conjugate (ADC) (44)
Approvals (3786)
Artificial intelligence (85)
Autoimmune disease (30)
Automation (6)
Bankruptcy (97)
Best Places to Work (2865)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (8)
Breast cancer (104)
Cancer (901)
Cardiovascular disease (63)
Career advice (395)
Career pathing (3)
CAR-T (65)
CDC (2)
Cell therapy (169)
Cervical cancer (5)
Clinical research (16712)
Collaboration (364)
Compensation (378)
Complete response letters (8)
COVID-19 (314)
CRISPR (13)
C-suite (352)
Cystic fibrosis (28)
Data (1353)
Denatured (2)
Depression (22)
Diabetes (79)
Diagnostics (2126)
Digital health (11)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (34)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (38)
Earnings (42831)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39179)
Executive appointments (434)
FDA (4428)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (345)
Gene editing (24)
Generative AI (7)
Gene therapy (104)
GLP-1 (145)
Government (428)
Guidances (197)
Healthcare (5050)
HIV (11)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (41)
Immuno-oncology (9)
Indications (18)
Infectious disease (342)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (8)
Intellectual property (33)
Interviews (53)
IPO (7880)
IRA (3)
Job creations (1122)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (106)
Leadership (5)
Legal (2338)
Liver cancer (21)
Longevity (2)
Lung cancer (98)
Lymphoma (72)
Machine learning (3)
Management (10)
Manufacturing (146)
MASH (52)
Medical device (3923)
Medtech (3933)
Mergers & acquisitions (7590)
Metabolic disorders (221)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (546)
NextGen: Class of 2026 (1674)
Non-profit (732)
Now hiring (5)
Obesity (89)
Opinion (32)
Ovarian cancer (26)
Pain (26)
Pancreatic cancer (38)
Parkinson's disease (51)
Partnered (6)
Patents (54)
Patient recruitment (101)
Peanut (6)
People (25258)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (5004)
Phase 2 (7240)
Phase 3 (5795)
Pipeline (2044)
Policy (17)
Postmarket research (625)
Preclinical (1950)
Press Release (66)
Prostate cancer (58)
Psychedelics (3)
Radiopharmaceuticals (110)
Rare diseases (184)
Real estate (1886)
Recruiting (8)
Regulatory (5557)
Reports (17)
Research institute (309)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (50)
Series A (53)
Series B (57)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (5)
Startups (1018)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (83)
Venture capital (10)
Weight loss (30)
Women's health (6)
Date
Today (57)
Last 7 days (194)
Last 30 days (627)
Last 365 days (8952)
2026 (1073)
2025 (9037)
2024 (11031)
2023 (13195)
2022 (18664)
2021 (19681)
2020 (18242)
2019 (13207)
2018 (10210)
2017 (10004)
2016 (9159)
2015 (12118)
2014 (9588)
2013 (7707)
2012 (8332)
2011 (8798)
2010 (8634)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (11801)
Australia (1694)
California (3603)
Canada (1154)
China (173)
Colorado (146)
Connecticut (168)
Delaware (71)
Europe (25551)
Florida (555)
Georgia (67)
Idaho (24)
Illinois (166)
India (19)
Indiana (108)
Iowa (9)
Japan (171)
Kansas (37)
Kentucky (17)
Louisiana (8)
Maine (52)
Maryland (356)
Massachusetts (2857)
Michigan (104)
Minnesota (203)
Mississippi (1)
Missouri (33)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1033)
New Mexico (5)
New York (831)
North Carolina (487)
North Dakota (4)
Northern California (1892)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (607)
Puerto Rico (2)
Rhode Island (19)
South America (279)
South Carolina (17)
Southern California (1328)
Tennessee (63)
Texas (493)
United States (12554)
Utah (111)
Virginia (86)
Washington D.C. (17)
Washington State (303)
West Virginia (2)
Wisconsin (61)
Wyoming (1)
232,330 Results for "fluidigm corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Danaher To Acquire Masimo Corporation
February 17, 2026
·
15 min read
Press Releases
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
February 11, 2026
·
4 min read
Biotech Bay
Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
Fluidigm Corporation announced that it has entered into a support agreement with Caligan Partners LP, Fluidigm’s current largest holder of common stock, under which Caligan has agreed to vote “FOR” all Fluidigm proposals related to the proposed strategic capital infusion transaction with Casdin Capital, LLC and Viking Global Investors LP at Fluidigm’s Special Meeting of Stockholders, which has been adjourned and will reconvene on April 1, 2022.
March 29, 2022
·
8 min read
Biotech Bay
Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Fluidigm Corporation announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event.
November 16, 2021
·
2 min read
Biotech Bay
Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference
Fluidigm Corporation announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event.
September 2, 2021
·
2 min read
Press Releases
Santhera Appoints Stifel as Corporate Finance Advisor
February 10, 2026
·
2 min read
Biotech Bay
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
Fluidigm Corporation announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP.
April 1, 2022
·
6 min read
Biotech Bay
Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
Fluidigm Corporation urged Fluidigm stockholders to vote “FOR” ALL proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP at the Company’s upcoming Special Meeting of Stockholders.
March 21, 2022
·
8 min read
Press Releases
Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference
February 18, 2026
·
1 min read
Biotech Bay
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
Fluidigm Corporation announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP. Fluidigm has been renamed Standard BioTools Inc. and its common stock is expected to begin trading on Nasdaq under the symbol “LAB” as of the open of market on April 6, 2022.
April 4, 2022
·
9 min read
1 of 23,233
Next
